- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Karo Bio AB (KA6)
| Open: | 0.039 | Day's Range: | 0.004 - 0.039 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.004 | 52wk Range: | 0.001 - 0.090 | 1-Yr Rtn: | -82.47% |
Key Statistics for KA6
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 533 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/12/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for KA6
Company Profile & Key Executives for KA6
Karo Bio AB operates a drug research and development company. The Company develops precision drugs to treat major diseases in the field of nuclear receptors. Karo Bio works within many therapeutic areas including men and women's health, cardiovascular diseases, metabolic disorders and dermatology.
| Goran WessmanChairman | Per BengtssonPresident & CEO |
| Lars OhmanVP:Business Development | Henrik PalmChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
KA6 News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page